Phase Ia Clinical Study of HDM1005 Injection

Summary

This is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase Ia clinical study. It is aimed to evaluate the safety, tolerability, PK and PD characteristics of HDM1005 injection in healthy adult subjects.

Timeline

Start

2024-03-19

Primary completion

2024-08-06

Completion

2024-09-26

Drugs

Indications